查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019145

動物疫苗市場機會、成長要素、產業趨勢分析及2026-2035年預測。

Animal Vaccines Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 142 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，全球動物疫苗市場價值將達到 142 億美元，並有望以 6.6% 的複合年成長率成長，到 2035 年達到 270 億美元。

動物疫苗市場 - IMG1

由於全球牲畜和寵物數量的增加、對動物性蛋白質需求的成長、寵物飼養率的上升以及獸醫保健支出的增加，該市場正在擴張。牲畜和伴侶動物感染疾病的傳播，以及人們對通用感染疾病和集體爆發風險日益成長的擔憂，正在推動疫苗的普及。世界各國政府和監管機構正在實施更嚴格的動物健康政策和疫苗接種計劃，以保護公眾健康並最大限度地減少畜牧業的經濟損失。獸醫技術的進步，包括疫苗配方和給藥系統的改進，進一步鞏固了市場。農民和寵物飼主對食品安全和疾病預防意識的提高，也持續推動了對有效動物免疫解決方案的需求，使疫苗成為全球動物健康管理的重要組成部分。

市場範圍
開始年份 2025
預測期 2026-2035
上市時的市場規模 142億美元
預測金額 270億美元
複合年成長率 6.6%

預計到2025年，畜牧業市場規模將達94億美元。畜牧業涵蓋牛、家禽、豬、水產養殖、綿羊和山羊，由於其在全球糧食生產中的重要經濟地位，成為推動市場成長要素。該行業的疫苗接種能夠預防感染疾病的爆發，避免對肉類、乳製品和雞蛋生產造成嚴重影響。政府和私人部門對畜牧業免疫計畫的大量投資正在推動疫苗需求成長，從而保障動物福利和經濟穩定。有效的疫苗接種方案有助於養殖戶有效率地管理疾病爆發，減少損失，並支持永續的畜牧業發展模式。

預計到2025年，病毒感染疾病領域將佔據55.3%的市場佔有率，到2035年將達到152億美元。病毒感染疾病仍然是牲畜和伴侶動物面臨的主要問題，因為它可能造成巨大的經濟和健康負擔。傳染性病毒疾病的高發生率推動了對標靶疫苗的需求，以預防大規模疫情的爆發。獸醫專業人員越來越重視病毒疫苗，將其視為保護畜群、提高生產力和維護食品安全標準的重要手段。

預計到2025年，北美動物疫苗市佔率將達到41.7%，並在2026年至2035年間以6.3%的複合年成長率成長。該地區的主導地位得益於先進的獸醫基礎設施、高額的動物保健支出以及大規模的畜牧養殖。強力的疾病預防計畫、龐大的動物存欄量以及政府主導的監測舉措進一步鞏固了北美的地位。美國憑藉其高疫苗接種率、獸醫專業知識以及領先的動物用藥品公司在研發和分銷網路方面的投入，為該地區的成長做出了重大貢獻。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章業界考察

  • 生態系分析
  • 影響產業的因素
    • 促進因素
      • 通用感染疾病發生率增加
      • 畜牧業擴張及對糧食安全的擔憂
      • 寵物數量的增加和動物醫療保健支出的增加。
      • 疫苗技術的進步
      • 動物疾病發生率增加
    • 產業潛在風險與挑戰
      • 高昂的開發成本
      • 嚴格的監管要求
    • 市場機遇
      • 新興市場獸醫保健基礎設施的擴張
      • 預防性獸醫學的廣泛應用
  • 成長潛力分析
  • 監理情勢（基於初步調查）
    • 北美洲
      • 美國
      • 加拿大
    • 歐洲
    • 亞太地區
  • 科技與創新趨勢
    • 目前技術
    • 新興科技及其影響
  • 臨床試驗和研發管線分析（基於初步調查）
  • 專利分析（基於初步研究）
  • 人工智慧對市場的影響
  • 波特五力分析
  • PESTEL 分析

第4章 競爭情勢

  • 介紹
  • 企業市佔率分析
    • 北美洲
    • 歐洲
    • 亞太地區
  • 企業矩陣分析
  • 主要市場公司的競爭分析
  • 競爭定位矩陣
  • 主要進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 業務拓展計劃

第5章 市場估算與預測：依動物種類分類，2022-2035年

  • 家畜
    • 家禽
    • 牛
    • 豬
    • 水產養殖
    • 綿羊和山羊
  • 伴侶動物
    • 狗
    • 貓
    • 馬
    • 鳥類

第6章 市場估計與預測：疫苗類型，2022-2035年

  • 減毒活病毒疫苗
  • 結合疫苗
  • 去活化疫苗
  • DNA疫苗
  • 重組疫苗
  • 其他疫苗類型

第7章 市場估計與預測：依應用領域分類，2022-2035年

  • 細菌感染疾病
  • 病毒感染疾病
  • 寄生蟲感染疾病
  • 黴菌感染疾病
  • 其他用途

第8章 市場估計與預測：依給藥途徑分類，2022-2035年

  • 注射疫苗
  • 口服疫苗
  • 浸泡/噴灑疫苗

第9章 市場估價與預測：依通路分類，2022-2035年

  • 獸藥
  • 普通藥房
  • 電子商務

第10章 市場估價與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第11章：公司簡介

  • Boehringer Ingelheim International
  • Brilliant Bio Pharma
  • Bioveta
  • Ceva Sante Animale
  • Dechra Pharmaceuticals
  • Elanco Animal Health
  • Henry Schein Animal Health（Covetrus, Inc.）
  • Hipra Animal Health Limited
  • Indian Immunologicals
  • Merck Animal Health
  • Neogen Corporation
  • Vetoquinol
  • Virbac
  • Zoetis
簡介目錄
Product Code: 3117

The Global Animal Vaccines Market was valued at USD 14.2 billion in 2025 and is estimated to grow at a CAGR of 6.6% to reach USD 27 billion by 2035.

Animal Vaccines Market - IMG1

The market is expanding due to rising global animal populations, growing demand for animal protein, increased adoption of pets, and higher veterinary care expenditure. The increasing prevalence of infectious diseases in livestock and companion animals, along with heightened concerns over zoonotic diseases and outbreak risks, has driven vaccine adoption. Governments and regulatory authorities worldwide are implementing stricter animal health policies and vaccination programs to safeguard public health and minimize economic losses in the livestock sector. Technological advancements in veterinary medicine, including improved vaccine formulations and delivery systems, further strengthen the market. Rising awareness of food security and disease prevention among farmers and pet owners has also created a sustained demand for effective animal immunization solutions, making vaccines a critical component of animal health management globally.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$14.2 Billion
Forecast Value$27 Billion
CAGR6.6%

The livestock animals segment generated USD 9.4 billion in 2025. The livestock segment, encompassing cattle, poultry, swine, aquaculture, and sheep and goats, is a key driver due to its economic significance in global food production. Vaccination in this sector prevents outbreaks of infectious diseases that could severely impact meat, dairy, and egg production. High private and government investments in livestock immunization programs fuel the demand for vaccines, ensuring both animal welfare and economic stability. Effective vaccination protocols help farmers manage disease outbreaks efficiently, reducing losses and supporting sustainable livestock farming practices.

The viral infections segment accounted for 55.3% share in 2025 and is expected to reach USD 15.2 billion by 2035. Viral infections remain a major concern for both livestock and companion animals, as diseases can cause significant economic and health burdens. The high prevalence of contagious viral conditions drives demand for targeted vaccines that prevent widespread outbreaks. Animal health professionals increasingly rely on viral vaccines as essential tools to protect animal populations, enhance productivity, and maintain food safety standards.

North America Animal Vaccines Market held a 41.7% share in 2025 and is anticipated to grow at a 6.3% CAGR during 2026-2035. The region's leadership is driven by advanced veterinary healthcare infrastructure, high animal healthcare spending, and extensive livestock production. Strong disease prevention programs, a large animal population, and government-backed monitoring initiatives further strengthen North America's position. The U.S. contributes significantly to regional growth due to robust vaccination adoption, veterinary expertise, and investments by major animal health companies in research, development, and distribution networks.

Key players in the Global Animal Vaccines Market include Boehringer Ingelheim International, Zoetis, Vetoquinol, Indian Immunologicals, Hipra Animal Health Limited, Dechra Pharmaceuticals, Merck Animal Health, Ceva Sante Animale, Elanco Animal Health, Neogen Corporation, Virbac, Brilliant Bio Pharma, Bioveta, and Henry Schein Animal Health (Covetrus, Inc.). Companies in the Global Animal Vaccines Market focus on expanding their presence by investing heavily in research and development to create innovative and highly effective vaccines. Strategic collaborations with veterinary clinics, distributors, and government programs help extend their market reach. Businesses leverage advanced manufacturing technologies to improve vaccine efficacy, reduce costs, and enhance delivery systems. Targeting emerging markets with rising livestock production and pet ownership ensures sustained growth. Marketing initiatives emphasize disease prevention, animal welfare, and economic benefits, building trust among farmers and pet owners. Participation in international trade shows, certification programs, and partnerships with animal health associations also strengthens brand recognition and competitive positioning globally.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research approach
  • 1.3 Quality commitments
    • 1.3.1 GMI AI policy and data integrity commitment
      • 1.3.1.1 Source consistency protocol
  • 1.4 Research trail and confidence scoring
    • 1.4.1 Research trail components
    • 1.4.2 Scoring components
  • 1.5 Data collection
    • 1.5.1 Partial list of primary sources
  • 1.6 Data mining sources
    • 1.6.1 Paid sources
      • 1.6.1.1 Sources, by region
  • 1.7 Base estimates and calculations
    • 1.7.1 Revenue share analysis
    • 1.7.2 Base year calculation
  • 1.8 Forecast model
  • 1.9 Research transparency addendum
    • 1.9.1 Source attribution framework
    • 1.9.2 Quality assurance metrics
    • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Animal type trends
    • 2.2.3 Vaccine type trends
    • 2.2.4 Application trends
    • 2.2.5 Route of administration trends
    • 2.2.6 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of zoonotic diseases
      • 3.2.1.2 Expanding livestock industry and food security concerns
      • 3.2.1.3 Increasing pet adoption and expenditure on animal health
      • 3.2.1.4 Advancements in vaccine technology
      • 3.2.1.5 Increasing outbreaks of animal diseases
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High development costs
      • 3.2.2.2 Stringent regulatory requirements
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion of veterinary healthcare infrastructure in emerging markets
      • 3.2.3.2 Increasing adoption of preventive veterinary care
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape (Driven by Primary Research)
    • 3.4.1 North America
      • 3.4.1.1 U.S.
      • 3.4.1.2 Canada
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology and innovation landscape
    • 3.5.1 Current technologies
    • 3.5.2 Emerging technologies and their impact
  • 3.6 Clinical trial/pipeline analysis (Driven by Primary Research)
  • 3.7 Patent analysis (Driven by Primary Research)
  • 3.8 Impact of AI on the market
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 North America
    • 4.2.2 Europe
    • 4.2.3 Asia Pacific
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Merger and acquisition
    • 4.6.2 Partnership and collaboration
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Animal Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Livestock animals
    • 5.2.1 Poultry
    • 5.2.2 Cattle
    • 5.2.3 Swine
    • 5.2.4 Aquaculture
    • 5.2.5 Sheep and goats
  • 5.3 Companion animals
    • 5.3.1 Canine
    • 5.3.2 Feline
    • 5.3.3 Equine
    • 5.3.4 Avian

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Attenuated live vaccine
  • 6.3 Conjugate vaccine
  • 6.4 Inactivated vaccine
  • 6.5 DNA vaccine
  • 6.6 Recombinant vaccine
  • 6.7 Other vaccine types

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Bacterial infections
  • 7.3 Viral infections
  • 7.4 Parasitic infections
  • 7.5 Fungal infections
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 Injection vaccines
  • 8.3 Oral vaccines
  • 8.4 Immersion/spray vaccines

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

  • 9.1 Key trends
  • 9.2 Veterinary hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Boehringer Ingelheim International
  • 11.2 Brilliant Bio Pharma
  • 11.3 Bioveta
  • 11.4 Ceva Sante Animale
  • 11.5 Dechra Pharmaceuticals
  • 11.6 Elanco Animal Health
  • 11.7 Henry Schein Animal Health (Covetrus, Inc.)
  • 11.8 Hipra Animal Health Limited
  • 11.9 Indian Immunologicals
  • 11.10 Merck Animal Health
  • 11.11 Neogen Corporation
  • 11.12 Vetoquinol
  • 11.13 Virbac
  • 11.14 Zoetis